Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

#TAPUR results of pembrolizumab in various tumors with HTMB extend KEYNOTE-158 data that led to FDA approval in tumors with HTMBPURPOSEThe Targeted Agent and Profiling Utilization Registry (TAPUR) ...

PURPOSEPembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

CHICAGO — The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for adults with advanced malignant pleural mesothelioma, according to results of the ...

Pembrolizumab, an anti-programmed death receptor-1 therapy, is marketed under the brand name Keytruda and is currently approved for 2 endometrial carcinoma indications: ...

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1), is currently marketed under the brand name Keytruda and is approved for 2 cervical cancer indications: ...